Laurus Labs Q2 FY27: consolidated PAT up 124% YoY to ₹436 Cr as OPM expands to 34%
PAT +124.27% YoY · revenue +33.44% · margins expanding
₹2,206.37 Cr
+33.44% YoY
₹436.19 Cr
+124.27% YoY
19.65%
+8.1pp YoY
₹8.17
Laurus Labs' consolidated PAT rose 124.3% YoY to ₹436.19 Cr (₹194.49 Cr in Q2 FY26) on revenue up 33.4% YoY to ₹2,206.37 Cr, and the print also builds sequentially — PAT +20.5% QoQ, revenue +8.9% QoQ over Q1 FY27's ₹362.07 Cr / ₹2,026.31 Cr. Consolidated is the primary basis here; standalone PAT grew a slower 80.0% YoY to ₹388.13 Cr (from ₹215.67 Cr) on 28.6% revenue growth, with the gap versus consolidated's 124.3% explained by subsidiary and non-controlling-interest contribution rather than any divergence in the core story.
Q2 FY-2027 vs prior quarters
The margin expansion is the bigger story than topline: OPM (EBITDA/revenue) widened to roughly 34.0% from 24.4% a year ago and 31.5% last quarter, while NPM rose to 19.65% from 11.57% YoY and 17.79% QoQ. The bridge sits mainly in other expenses, which fell to ~17.0% of revenue from ~22.4% YoY, and in depreciation leverage (5.8% of revenue vs 7.3% YoY) as the base business scales — cost of materials consumed stayed roughly flat at ~41% of revenue, consistent with management's prior comment that raw-material headwinds persist.
The stock went into the print at ₹2,216.5, up 10.2% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
Basic EPS ₹8.17 vs ₹3.61 in Q2 FY26 and ₹6.81 in Q1 FY27.
FY27 capex raised to ₹2,000 Cr from ₹1,500 Cr (may exceed); targeting 50% CDMO revenue by FY30; ROCE to grow from 19% toward 25% target; margin sustainability expected despite raw material headwinds.
— This quarter: beat
Management's July 2026 concall guided to 'margin sustainability despite raw material headwinds' and an ROCE climb from 19% toward a 25% target; this quarter's expansion goes well beyond mere sustainability, so the print reads as a beat against that qualitative bar, though ROCE itself isn't independently computable from this statement. No formal Street consensus for Q2 FY27 PAT/revenue turned up in search, and the company's own press release commentary on this result hasn't been extracted yet, so neither vs-Street nor management framing can be cross-checked beyond the filed numbers. Alongside the results, the board approved an interim dividend of ₹1.00/share (50% of the ₹2 face value, record date November 6, 2026) and the quarter also saw a ₹107.8 Cr investment in the 49%-held KRKA Pharma JV, consistent with the CDMO capacity push behind the FY27 capex guidance raised to ₹2,000 Cr from ₹1,500 Cr; H1 FY27 consolidated capex spend of ₹864.19 Cr is running well below half that revised full-year number so far.
W1
FY27 capex guidance raised to ₹2,000 Cr from ₹1,500 Cr — H1 FY27 consolidated PP&E spend was ₹864.19 Cr; watch H2 pace against the full-year number.
W2
CDMO revenue mix target of 50% by FY30 — no segment split disclosed this quarter; watch for progress disclosure in coming quarters.
W3
ROCE trajectory toward management's 25% target from 19% — not computable from this statement; watch next quarter's commentary for an update.
Consolidated PAT ₹436.19 Cr = Net Profit after tax ₹436.74 Cr less ₹0.55 Cr share of associate/JV loss, before NCI of -₹5.29 Cr (equity-holder PAT ₹441.48 Cr); standalone PAT growth (+80.0% YoY) trails consolidated (+124.3% YoY) on subsidiary/minority contribution. No exceptional items in current or year-ago period, so raw = underlying growth.
Margin Hold Key as CDMO Momentum Tested
Laurus Labs reports Q2 FY27 results on October 29 with strong Q1 momentum in focus. The Street watches whether the company can sustain its 31.5% EBITDA margin and continue CDMO's 69% growth surge, amid a ₹2,000 Cr capex ramp and strategic investments in renewables and the KRKA joint venture.
The Setup
Laurus Labs delivered a record Q1 FY27 (Jun 30, 2026) with revenue of ₹2,026 Cr (+29% YoY) and EBITDA margin of 31.5% — a 670-bp lift from the prior-year quarter. The CDMO segment, the growth engine, surged 69% to ₹835 Cr, while the generics portfolio added ₹1,191 Cr. On October 29, the board will present Q2 FY27 (Sep 30, 2026) results. The Street consensus is Neutral (7 Buy, 3 Hold, 4 Sell), with a 12-month consensus target of ₹1,486 and recent analyst cites from Citi (Hold, ₹1,720) and Motilal Oswal (Buy, ₹1,110). The stock trades at ₹2,002.5, 4% below ATH, and 41% above its 200-day MA, suggesting strong momentum but potential valuation debate.
~₹1,950–2,050 Cr
Assuming sequential stability or slight uplift; Q1 base ₹2,026 Cr
~30–32%
Q1 set bar at 31.5%; management guided 'maintained or improved'
Watch momentum
Q1 +69% YoY (₹835 Cr); currency headwinds + supply/capacity risks
~₹320–360 Cr
At prior-year tax/interest rates; depends on capex depreciation & JV share
A strong print for Q2 would hold or expand margin above 30%, post CDMO growth >50% YoY, and show revenue within the ₹1,950–2,050 Cr range with mix toward high-margin commercial supplies. A weak print would show margin compression below 29%, CDMO growth <30%, or generics de-growth from competitive/pricing pressure. Currency headwinds (INR strength vs USD) and inventory normalization post-Q1 surge are the primary swing factors.
On Track?
Laurus Labs has guided FY27 EBITDA margins to be 'maintained or improved' — meaning 31%+ is on-plan, not a beat. Q1 established the run-rate: ₹2,026 Cr revenue + 31.5% margin = ~₹644 Cr EBITDA, a 66% YoY jump. Management also raised CapEx guidance to ₹2,000 Cr (from ₹1,500 Cr) to meet CDMO demand. This signals confidence in the trajectory. The October demerger of the Synthetics segment (approved by NCLT on Jul 25) will affect consolidated results in Q2 onwards — watch whether standalone EBITDA of continuing operations holds the 30%+ bar. Recent filings (₹107.8 Cr KRKA JV investment, ₹12.1 Cr KRPL renewable stake) indicate strategic capex deployment, not cash pressure, but dilute near-term profit growth as these investments are equity holds with likely carry-forward losses or low dividends initially.
Street View
Since Last Quarter
1 · Synthetics Demerger (Jul 25)
NCLT approved the Composite Scheme of Arrangement involving demerger of Laurus Synthetics. This will separate the pharmacopoeia/intermediates business from the main CDMO/generics platform. Q2 consolidated results will begin excluding Synthetics P&L (if effective date Tone: Routine but structural.
2 · KRKA Joint Venture Investment (Oct 14)
Laurus invested ₹107.8 Cr in KRKA Pharma Private Limited, a JV with KRKA d.d. (Novo Mesto, Slovenia) via rights issue. KRKA is a mid-size Central European generic/specialty pharma player — this is a minority equity stake to co-develop/distribute therapies in select markets. The investment is strategic (geographic/portfolio diversification) but non-accretive in Year 1 (equity-accounted, no dividend expected). Dilutes standalone RoE slightly but signals management confidence in capital deployment despite CapEx ramp. Tone: Good (growth), but watch for execution delays.
3 · Renewables Investment (Oct 6)
Laurus invested ₹12.1 Cr in Kurnool Renewables Private Limited (KRPL), an associate. This is a capex ESG play — likely solar/wind capacity for internal use and/or renewable credits to offset carbon footprint ahead of possible carbon tax / ESG rating impacts. Non-core but consistent with CareEdge ESG 1+ rating achieved in Oct. Negligible on P&L but shows disciplined allocation to long-tail ESG risks. Tone: Routine/positive.
4 · ESG Ratings (Oct 14 & prior Aug 10)
Laurus Labs assigned CareEdge-ESG 1+ (82.6/100) in Oct. Prior NSE Sustainability Rating was 63/100 (Aug 2026). Ratings are improving, signaling better ESG governance and risk management — likely to help with FII inflows (especially if MSCI/S&P indices raise weightage). No immediate P&L impact, but supports long-term valuation re-rating. Tone: Good (intangible but positive for multiples).
5 · Insider/Bulk Trading (Aug–Sep 2026)
Bulk deals in late Aug (BNP Paribas, Integrated Core Strategies) at ₹1,860–1,922 range (note: now at ₹2,002.5, so +4–7% appreciation since). Trading window closed Sep 25 ahead of Oct 29 results — no material insider buying/selling to flag. Promoter holding stable at ~27.5% (minimal pledge/dilution risk). FII holdings rose +2.18pp QoQ to 28% in Q1 (strongest ownership cohort). Tone: Routine, no red flags.
Summary: The demerger is the biggest structural change — confirm whether it's accounted for in Q2 consolidated numbers or still pending. The KRKA/KRPL investments are strategic but non-accretive near-term; monitor for integration/launch milestones. No material insider/promoter risk or governance red flags. Momentum is with FII (up 2.18pp QoQ) and ESG improving, both supportive of the current valuation.
What to Watch on October 29
Laurus Labs will deliver Q2 FY27 results on a backdrop of strong Q1 momentum, a demerger underway, and significant capex deployment. The key questions for the print: (1) Revenue sustainability: Does the company hold ~₹2,000 Cr+ quarterly run-rate, or does Q2 see seasonal softness / currency headwinds? (2) EBITDA margin: Can it maintain or beat the 31.5% Q1 bar, or does a less favorable product mix (more generics vs CDMO commercial supplies) pull margins down? (3) CDMO momentum: Is the 69% YoY growth sustainable, or does input cost inflation / capacity constraints cool growth Demerger impact: Is Synthetics fully demerged or still consolidated? Standalone margins of continuing ops are the true test of durability. (5) Guidance affirmation: Does management reaffirm FY27 margin guidance, or do Q2 headwinds warrant a trim? Watch the earnings call tone on capex ROI and CDMO customer wins to gauge FY27 growth trajectory. A margin hold + CDMO >50% growth would validate the bull case; margin compression + growth slowdown would invite Street buying on valuation (or underperformance).
Laurus Labs enters Q2 FY27 with a record Q1 and buoyant momentum. The Street is split on valuation but united on the CDMO platform as the multi-year growth driver. The key test is margin sustainability — whether the 31.5% EBITDA margin is a new run-rate or a Q1 peak. The demerger adds structural complexity; watch for clean separation and standalone margin clarity. If management holds margins and CDMO growth above 50%, the stock likely extends its recent rally; if margins compress or growth cools, valuation re-rating risk rises despite strong absolute growth. Currency (INR/USD), input costs (APIs, excipients), and competitive intensity in generics are the primary downside levers on the quarter.